Correlation Between Novo Nordisk and Genscript Biotech

Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Genscript Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Genscript Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novo Nordisk AS and Genscript Biotech, you can compare the effects of market volatilities on Novo Nordisk and Genscript Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Genscript Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Genscript Biotech.

Diversification Opportunities for Novo Nordisk and Genscript Biotech

0.43

Correlation Coefficient

Novo Nordisk  Genscript Biotech

Very weak diversification

The 3 months correlation between Novo and Genscript is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Genscript Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genscript Biotech and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Genscript Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genscript Biotech has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Genscript Biotech go up and down completely randomly.

Pair Corralation between Novo Nordisk and Genscript Biotech

Assuming the 90 days trading horizon Novo Nordisk is expected to generate 8.79 times less return on investment than Genscript Biotech. But when comparing it to its historical volatility, Novo Nordisk AS is 1.75 times less risky than Genscript Biotech. It trades about 0.04 of its potential returns per unit of risk. Genscript Biotech is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  124.00  in Genscript Biotech on April 25, 2025 and sell it today you would earn a total of  68.00  from holding Genscript Biotech or generate 54.84% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Novo Nordisk AS  vs.  Genscript Biotech

Novo Nordisk AS

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, Novo Nordisk is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Genscript Biotech

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Genscript Biotech are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Genscript Biotech reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Novo Nordisk and Genscript Biotech

The main advantage of trading using opposite Novo Nordisk and Genscript Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Genscript Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genscript Biotech will offset losses from the drop in Genscript Biotech's long position.

The idea behind Novo Nordisk AS and Genscript Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.